Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;98:839-844

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ridker, P. M.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridker, P. M.
Right arrow Articles by Braunwald, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cardiomyopathy
*Heart Attack
Hazardous Substances DB
*CHOLESTEROL

(Circulation. 1998;98:839-844.)
© 1998 American Heart Association, Inc.


Clinical Investigation and Reports

Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels

Paul M. Ridker, MD; Nader Rifai, PhD; Marc A. Pfeffer, MD; Frank M. Sacks, MD; Lemuel A. Moye, MD, PhD; Steven Goldman, MD; Greg C. Flaker, MD; Eugene Braunwald, MD; ; for the Cholesterol and Recurrent Events (CARE) Investigators

From the Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (P.M.R., M.A.P., F.M.S., E.B.); the Children's Hospital Medical Center, Boston (N.R.); the University of Texas School of Public Health, Houston (L.A.M.); the Veterans Administration Medical Center, Tucson, Ariz (S.G.); and the University of Missouri, Columbia (G.C.F.).

Correspondence to Dr Paul M. Ridker, Division of Cardiovascular Diseases, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail pmridker{at}bics.bwh.harvard.edu

Background—We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk.

Methods and Results—A nested case-control design was used to compare C-reactive protein (CRP) and serum amyloid A (SAA) levels in prerandomization blood samples from 391 participants in the Cholesterol and Recurrent Events (CARE) trial who subsequently developed recurrent nonfatal MI or a fatal coronary event (cases) and from an equal number of age- and sex-matched participants who remained free of these events during follow-up (control subjects). Overall, CRP and SAA were higher among cases than control subjects (for CRP P=0.05; for SAA P=0.006) such that those with levels in the highest quintile had a relative risk (RR) of recurrent events 75% higher than those with levels in the lowest quintile (for CRP RR=1.77, P=0.02; for SAA RR=1.74, P=0.02). The study group with the highest risk was that with consistent evidence of inflammation (elevation of both CRP and SAA) who were randomly assigned to placebo (RR=2.81, P=0.007); this risk estimate was greater than the product of the individual risks associated with inflammation or placebo assignment alone. In stratified analyses, the association between inflammation and risk was significant among those randomized to placebo (RR=2.11, P=0.048) but was attenuated and nonsignificant among those randomized to pravastatin (RR=1.29, P=0.5).

Conclusions—Evidence of inflammation after MI is associated with increased risk of recurrent coronary events. Therapy with pravastatin may decrease this risk, an observation consistent with a nonlipid effect of this agent.


Key Words: C-reactive protein • serum amyloid A • myocardial infarction • atherosclerosis • cholesterol




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. M Ridker
The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1222 - 1224.
[Full Text] [PDF]


Home page
CirculationHome page
M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, and for the Cholesterol and Recurrent Events (CARE) Tr
Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease
Circulation, January 15, 2008; 117(2): 163 - 168.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello
Role of Inflammation in Atherosclerosis
J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. S. Gortney and R. M. Sanders
Impact of C-reactive protein on treatment of patients with cardiovascular disease
Am. J. Health Syst. Pharm., October 1, 2007; 64(19): 2009 - 2016.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Rydgren, O. Vaarala, and S. Sandler
Simvastatin Protects against Multiple Low-Dose Streptozotocin-Induced Type 1 Diabetes in CD-1 Mice and Recurrence of Disease in Nonobese Diabetic Mice
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 180 - 185.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
H. Blangy, N. Sadoul, B. Dousset, A. Radauceanu, R. Fay, E. Aliot, and F. Zannad
Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction
Europace, September 1, 2007; 9(9): 724 - 729.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. M. Maki-Petaja, A. D. Booth, F. C. Hall, S. M.L. Wallace, J. Brown, C. M. McEniery, and I. B. Wilkinson
Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 852 - 858.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. A. Lawson, K. K. Miller, V. A. Mathur, M. Misra, E. Meenaghan, D. B. Herzog, and A. Klibanski
Hormonal and Nutritional Effects on Cardiovascular Risk Markers in Young Women
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3089 - 3094.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Kitayama, F. M. Faraci, S. R. Lentz, and D. D. Heistad
Cerebral Vascular Dysfunction During Hypercholesterolemia
Stroke, July 1, 2007; 38(7): 2136 - 2141.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M.S. Kostapanos, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf
Do statins have an antiarrhythmic activity?
Cardiovasc Res, July 1, 2007; 75(1): 10 - 20.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Ridker
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman
Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans
Circulation, May 29, 2007; 115(21): 2715 - 2721.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. E. Szmitko and S. Verma
C-Reactive Protein and Reendothelialization: NO Involvement
Circ. Res., May 25, 2007; 100(10): 1405 - 1407.
[Full Text] [PDF]


Home page
CirculationHome page
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Circulation, April 3, 2007; 115(13): e356 - e375.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Clin. Chem., April 1, 2007; 53(4): 552 - 574.
[Full Text] [PDF]


Home page
CirculationHome page
M. S. Sabatine, D. A. Morrow, K. A. Jablonski, M. M. Rice, J. W. Warnica, M. J. Domanski, J. Hsia, B. J. Gersh, N. Rifai, P. M Ridker, et al.
Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease
Circulation, March 27, 2007; 115(12): 1528 - 1536.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Sattar, H. M. Murray, A. McConnachie, G. J. Blauw, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, et al.
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Circulation, February 27, 2007; 115(8): 981 - 989.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
E Hothersall, C McSharry, and N C Thomson
Potential therapeutic role for statins in respiratory disease.
Thorax, August 1, 2006; 61(8): 729 - 734.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. D. Wiviott, M. A. Blazing, A. Shui, N. Rifai, R. M. Califf, and E. Braunwald
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Circulation, July 25, 2006; 114(4): 281 - 288.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
N. R. Cook, J. E. Buring, and P. M Ridker
The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women
Ann Intern Med, July 4, 2006; 145(1): 21 - 29.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Tsimikas, J. T. Willerson, and P. M. Ridker
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Hermann and F. Ruschitzka
Novel anti-inflammatory drugs in hypertension
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864.
[Full Text] [PDF]


Home page
HeartHome page
D Tousoulis, M Charakida, and C Stefanadis
Endothelial function and inflammation in coronary artery disease
Heart, April 1, 2006; 92(4): 441 - 444.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
K. W.J. Lee, J. S. Hill, K. R. Walley, and J. J. Frohlich
Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort.
Can. Med. Assoc. J., February 14, 2006; 174(4): 461 - 466.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
P. Libby
Inflammation and cardiovascular disease mechanisms
Am. J. Clinical Nutrition, February 1, 2006; 83(2): 456S - 460S.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Ronnemaa
High-Sensitivity C-Reactive Protein and Coronary Heart Disease Mortality in Patients With Type 2 Diabetes: A 7-year follow-up study
Diabetes Care, February 1, 2006; 29(2): 329 - 333.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Boos, R. A. Anderson, and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?
Eur. Heart J., January 2, 2006; 27(2): 136 - 149.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Christodoulides, P. N. Floriano, S. A. Acosta, K. L. M. Ballard, S. E. Weigum, S. Mohanty, P. Dharshan, D. Romanovicz, and J. T. McDevitt
Toward the Development of a Lab-on-a-Chip Dual-Function Leukocyte and C-Reactive Protein Analysis Method for the Assessment of Inflammation and Cardiac Risk
Clin. Chem., December 1, 2005; 51(12): 2391 - 2395.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Tomai, F. Ribichini, A. S. Ghini, V. Ferrero, G. Ando, C. Vassanelli, F. Romeo, F. Crea, and L. Chiariello
Elevated C-reactive protein levels and coronary microvascular dysfunction in patients with coronary artery disease
Eur. Heart J., October 2, 2005; 26(20): 2099 - 2105.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. A. Lakka, H.-M. Lakka, T. Rankinen, A. S. Leon, D.C. Rao, J. S. Skinner, J. H. Wilmore, and C. Bouchard
Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study
Eur. Heart J., October 1, 2005; 26(19): 2018 - 2025.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. P. Tam, J. B. Ancsin, R. Tan, and R. Kisilevsky
Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice
J. Lipid Res., October 1, 2005; 46(10): 2091 - 2101.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen
Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
M. B. Clearfield
C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease
J Am Osteopath Assoc, September 1, 2005; 105(9): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. G. Best, Y. Zhang, E. T. Lee, J.-L. Yeh, L. Cowan, V. Palmieri, M. Roman, R. B. Devereux, R. R. Fabsitz, R. P. Tracy, et al.
C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes: The Strong Heart Study
Circulation, August 30, 2005; 112(9): 1289 - 1295.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al.
Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members
Stroke, June 1, 2005; 36(6): 1316 - 1329.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Ridker, D. A. Morrow, L. M. Rose, N. Rifai, C. P. Cannon, and E. Braunwald
Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l: An Analysis of the PROVE-IT TIMI-22 Trial
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1644 - 1648.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
B. J. Nicklas, T. You, and M. Pahor
Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training
Can. Med. Assoc. J., April 26, 2005; 172(9): 1199 - 1209.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. A.H. Stewart, H. D. White, A. C. Kirby, S. R. Heritier, R. J. Simes, P. J. Nestel, M. J. West, D. M. Colquhoun, A. M. Tonkin, and for the Long-Term Intervention With Pravastatin in
White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin
Circulation, April 12, 2005; 111(14): 1756 - 1762.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. D. O'Brien, B. J. Brehm, R. J. Seeley, J. Bean, M. H. Wener, S. Daniels, and D. A. D'Alessio
Diet-Induced Weight Loss Is Associated with Decreases in Plasma Serum Amyloid A and C-Reactive Protein Independent of Dietary Macronutrient Composition in Obese Subjects
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2244 - 2249.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. D. O'Brien, T. O. McDonald, V. Kunjathoor, K. Eng, E. A. Knopp, K. Lewis, R. Lopez, E. A. Kirk, A. Chait, T. N. Wight, et al.
Serum Amyloid A and Lipoprotein Retention in Murine Models of Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 785 - 790.
[Abstract] [Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
R. Samson
Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2005; 17(1): 65-1 - 67.
[Abstract] [PDF]


Home page
J. Lipid Res.Home page
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res., March 1, 2005; 46(3): 389 - 403.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
V. M. Campese, M. K. Nadim, and M. Epstein
Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
P. Bogaty, J. M. Brophy, L. Boyer, S. Simard, L. Joseph, F. Bertrand, and G. R. Dagenais
Fluctuating Inflammatory Markers in Patients With Stable Ischemic Heart Disease
Arch Intern Med, January 24, 2005; 165(2): 221 - 226.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. M Ridker, C. P. Cannon, D. Morrow, N. Rifai, L. M. Rose, C. H. McCabe, M. A. Pfeffer, E. Braunwald, and the Pravastatin or Atorvastatin Evaluation and Inf
C-Reactive Protein Levels and Outcomes after Statin Therapy
N. Engl. J. Med., January 6, 2005; 352(1): 20 - 28.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Davi, M. Neri, A. Falco, D. Festi, T. Taraborelli, G. Ciabattoni, S. Basili, F. Cuccurullo, and C. Patrono
Helicobacter Pylori Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation
Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 246 - 251.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. M. Biasucci
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
Circulation, December 21, 2004; 110(25): e560 - e567.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
S Van Doornum, G McColl, and I P Wicks
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis
Ann Rheum Dis, December 1, 2004; 63(12): 1571 - 1575.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Amarenco, J. Labreuche, P. Lavallee, and P.-J. Touboul
Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Stroke, December 1, 2004; 35(12): 2902 - 2909.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Zanchetti, G. Crepaldi, M. G. Bond, G. Gallus, F. Veglia, G. Mancia, A. Ventura, G. Baggio, L. Sampieri, P. Rubba, et al.
Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS--A Randomized Double-Blind Trial
Stroke, December 1, 2004; 35(12): 2807 - 2812.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Madjid, I. Awan, J. T. Willerson, and S. W. Casscells
Leukocyte count and coronary heart disease: Implications for risk assessment
J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1945 - 1956.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Becker and M. Chopp
Role of Statins in the Treatment and Prevention of Stroke: Introduction
Stroke, November 1, 2004; 35(11_suppl_1): 2706 - 2707.
[Full Text] [PDF]


Home page
Circulation